Debra Ainge

Iethico Ltd. is a British company that aims to reduce the impact of medicine shortages and provide faster access to medicine. The company is based in Coventry, UK. The company links pharmacists to suppliers to bridge the gap between medicine access and supply. The company delivers insights to minimize medicine shortage impact through AI. The company was founded in 2021 by Renee Kalia, Claudio Zurzica. Debra Ainge has been the CEO of the company since 2020.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.

Iethico Ltd. is a British company that aims to reduce the impact of medicine shortages and provide faster access to medicine. The company is based in Coventry, UK. The company links pharmacists to suppliers to bridge the gap between medicine access and supply. The company delivers insights to minimize medicine shortage impact through AI. The company was founded in 2021 by Renee Kalia, Claudio Zurzica. Debra Ainge has been the CEO of the company since 2020.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.